Lorena Fiad

Outcomes of CHOP versus CHOEP/EPOCH in aggressive adult T-cell leukemia/lymphoma: an international cohort analysis

Aggressive adult T-cell leukemia/lymphoma (ATL) subtypes (i.e., acute and lymphomatous) are rare diseases, and the conventional management with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has historically yielded poor outcomes. The benefit of etoposide-conta...

Long‐term follow‐up of PET / CT ‐adapted therapy after three cycles of ABVD for all stages of classic Hodgkin lymphoma: Results of the GATLA LH ‐05 trial

Summary The Grupo Argentino de Tratamiento de la Leucemia Aguda (GATLA) LH‐05 trial evaluated positron emission tomography‐computed tomography (PET‐CT)‐guided ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) in patients with stage I–IV classic Hodgkin lymphoma (cHL). A...